Shattuck Labs, Inc. earnings releases STTK

Shattuck Labs, Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $0 (-100.0% year over year) and diluted EPS of -$0.14. It usually reports 36–64 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 4, 2027.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–64 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Nov 5, 2026
36 days after quarter end
Q3 FY2026
ended Sep 30, 2026
0
-100.0%
-25
-150.6%
-0.14
+0.0%
Aug 11, 2026
42 days after quarter end
Q2 FY2026
ended Jun 30, 2026
0
-15
-21.6%
-0.12
+50.0%
May 7, 2026
37 days after quarter end
Q1 FY2026
ended Mar 31, 2026
0
-15
-7.8%
-0.13
+51.9%
Mar 5, 2026
64 days after quarter end
Q4 FY2025
ended Dec 31, 2025
0
-13
+32.6%
0.00
+100.0%
Nov 6, 2025
37 days after quarter end
Q3 FY2025
ended Sep 30, 2025
1
-66.6%
-10
+39.7%
-0.14
+57.6%
Aug 14, 2025
45 days after quarter end
Q2 FY2025
ended Jun 30, 2025
0
-100.0%
-12
+42.2%
-0.24
+42.9%
May 1, 2025
31 days after quarter end
Q1 FY2025
ended Mar 31, 2025
0
-100.0%
-14
+26.0%
-0.27
+27.0%
Nov 14, 2024
45 days after quarter end
—
ended Sep 30, 2024
—
—
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
STTK (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Austin, TX
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1680367
Former names
Shattuck Labs, Inc. (until Nov 5, 2026)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.